Ziprasidone and Buprenorphine: Interaction Details
- Buprenorphine
- ButransBelbucaSublocade +2 more
- Ziprasidone
- Geodon
Medically reviewed by Dr. Brian Staiger, PharmD, BCPS
Also reviewed by the HelloPharmacist Editorial Team Updated AI-assisted Details about this page
- Dr. Brian Staiger, PharmD, BCPS, is a clinical pharmacist and pharmacotherapy specialist.
- AI-assisted, written
- AI is used only to summarize verified clinical information, never the open internet.
- Editorial policy
- How we build our interaction pages →
- Our AI policy →
A close look at the Ziprasidone and Buprenorphine interaction:
Buprenorphine
- Butrans
- Belbuca
- Sublocade
- Buprenex
- Brixadi
What Happens When You Take Ziprasidone With Buprenorphine
What can happen when they are taken together (rated Contraindicated)
An increased risk of , an increased risk of and an increased risk of respiratory and
Interaction Deep Dive
A note from Dr. Brian Staiger If you’re a patient, this deep dive may be too technical, or bore you (or both). Read the plain-language explanation →
Ziprasidone and buprenorphine should not be used together, because the combination can raise the risk of QT prolongation and serious ventricular . Buprenorphine taken with ziprasidone may also heighten the risk of serotonin syndrome and add to CNS depression.1
When the two cannot be kept apart, watch for serotonin syndrome, especially at the start of therapy and whenever doses are changed. If serotonin syndrome is suspected, buprenorphine should be stopped.3
Patients on depressants, ziprasidone included, should be denied access to medication-assisted treatment (MAT) drugs such as buprenorphine. Combined use does raise the risk of serious adverse effects, overdose, and death, but withholding MAT may carry a greater risk of morbidity and mortality from use disorder.
In most cases it is preferable to discontinue the CNS depressant. If using both is necessary, monitor carefully and manage with caution; options include tapering the CNS depressant to the lowest effective dose or choosing alternative treatments for anxiety or insomnia.2
The Ziprasidone and Buprenorphine Interaction, Explained
Taking buprenorphine and ziprasidone together can add up to several risks. Both medicines can affect your heart rhythm (called ), which in rare cases can cause a dangerous irregular heartbeat. Both can also make you very sleepy and slow your breathing. Buprenorphine may also raise the chance of , a reaction with agitation, sweating, shaking, fast heartbeat, and fever.
Because of these risks, this pairing is usually avoided. Please do not stop either medicine on your own, especially buprenorphine for use disorder, since stopping can carry its own serious risks. Talk with your pharmacist or doctor right away. Your care team can review your options, adjust doses, and watch you more closely. Get urgent help if you feel faint, have a racing or fluttering heartbeat, or have trouble breathing.
(evidence: probable). Buprenorphine plus ziprasidone has effects; onset unspecified.
- : additive risk of QTc prolongation and ventricular (including ).
- : additive .
- /: additive effects.
Management: Avoid when possible; discontinuing the CNS depressant is generally preferred. If use is unavoidable, monitor and manage cautiously (consider and electrolytes), watch for serotonin syndrome especially at initiation and dose changes, and stop buprenorphine if suspected. Consider tapering the CNS depressant to the lowest effective dose or using alternatives. Do not withhold MAT, as untreated OUD carries greater morbidity and mortality risk.
See the 3 references behind this explanation ↓
From the HelloPharmacist Pharmacy Team
AI-assisted: written with AI from this pair’s record in our interaction database, and reviewed by the HelloPharmacist pharmacy team. Written .
How we build these pages · How we use AI · Our editorial policy
Why Ziprasidone and Buprenorphine Interact
The likely mechanism
; additive ; additive
How to Manage the Ziprasidone and Buprenorphine Interaction
This combination is normally avoided, but your care team can weigh the risks and tailor a plan for you.
- Keep taking both medicines as prescribed until you speak with your prescriber or pharmacist. Do not stop buprenorphine on your own.
- Your team may consider lowering the dose of one medicine or choosing an alternative for the condition ziprasidone treats. Doses may need to be adjusted and individualized.
- Your team may monitor you more closely, especially when starting or changing doses.
- Tell them about any fainting, palpitations, extreme drowsiness, slowed breathing, agitation, sweating, tremor, or fever.
- Avoid alcohol and other sedating medicines unless your team approves.
Management is individual — confirm any change with your pharmacist or prescriber.
Questions for Your Pharmacist
- Does my dose of Ziprasidone or Buprenorphine need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there another option that avoids this interaction?
Literature Reports
2 reports from the published literature. Each one is headed by the title of the published study it comes from.
What these reports are. Short summaries of published evidence on this combination: clinical studies, case reports and, at times, the FDA prescribing information for one of the drugs. They support this interaction, but it does not rest on them alone. It can also rest on prescribing information not summarized here, or on what is expected from how these two drugs, and others in their drug classes, are known to work.
-
Report 1 · Study title
Drug Safety Communications: FDA urges caution about withholding opioid addiction medications from patients taking benzodiazepines or CNS depressants: careful medication management can reduce risks
A Swedish epidemiological study reported that patients on methadone- or buprenorphine-based medication-assisted treatment (MAT) who also received or other depressants (eg, drugs used to treat insomnia) had an increased risk of death. For the period from July 1, 2005 to December 31, 2012, the investigators analyzed the risk of fatal overdose, non-overdose related mortality, and all-cause mortality in MAT patients (aged 18 to 50), comparing periods with prescribed CNS depressants to periods without CNS depressant therapy.
Combined MAT and benzodiazepine treatment was associated with an elevated risk of all-cause mortality (adjusted hazard ratio (HR) 1.44; 95% CI, 0.93 to 2.23) and non-overdose related mortality (HR 1.74; 95% CI 1.00 to 3.01), but these findings were not considered statistically significant. During periods of of MAT and non-benzodiazepines, the risks of fatal overdose, non-overdose mortality, and all-cause mortality were all elevated, yet only fatal overdose and all-cause mortality reached statistical significance, with an HR of 2.34 (95% CI, 1.37 to 3.99) and an HR of 1.33 (95% CI, 1.12 to 2.45), respectively. When the benzodiazepine cohort and the non-benzodiazepine cohort were compared with each other, the non-benzodiazepine cohort findings also lost statistical significance.2
-
Report 2 · Study title
Drug Safety Communications: FDA urges caution about withholding opioid addiction medications from patients taking benzodiazepines or CNS depressants: careful medication management can reduce risks
A study of aggregate nationwide death certificate data from 2010 to 2014 identified 3495 drug overdose deaths reported in 2014. Methadone and other depressants were often listed as contributors to these deaths.
of ALPRAZolam was reported in 18.1% of cases, followed by oxyCODONE (10.1%), cocaine (9.6%), heroin (9%), and diazePAM (6.6%). The FDA reported 322 drug overdose deaths involving buprenorphine in 2014.
Among these 322 deaths, 32.9% involved ALPRAZolam, 17.4% involved clonazePAM, 11.2% involved diazePAM, 11.2% involved heroin, and 9.9% involved fentaNYL. The absolute number of deaths involving methadone was 10 times that of deaths involving buprenorphine, although confounding factors and differences in drug utilization were not taken into account. Whether the risk of overdose death with CNS depressant drugs differed between buprenorphine and methadone is unknown.2
Ziprasidone and Buprenorphine: Common Questions
How serious is the Ziprasidone and Buprenorphine interaction?
It is rated . These should generally not be used together.
How is the Ziprasidone and Buprenorphine interaction managed?
This combination is normally avoided, but your care team can weigh the risks and tailor a plan for you. Keep taking both medicines as prescribed until you speak with your prescriber or pharmacist. Do not stop buprenorphine on your own. Your team may consider lowering the dose of one medicine or choosing an alternative for the condition ziprasidone treats. Doses may need to be adjusted and individu… Management is individual — always follow your own care team's guidance.
Is there an alternative to taking Ziprasidone with Buprenorphine?
Your team may consider lowering the dose of one medicine or choosing an alternative for the condition ziprasidone treats.
Only your prescriber can decide whether a change fits you, so talk with them before changing either medicine.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How strong is the evidence for this interaction?
The evidence is graded "probable". Good supporting evidence, though not definitively proven.
Ask About the Ziprasidone and Buprenorphine Interaction
Ask in your own words about taking Ziprasidone and Buprenorphine together. The answer comes from this page’s interaction record and both drugs’ own information.
This box answers questions about this one combination only. For anything else about either drug, open its drug information page or ask a pharmacist.
AI answers from this page’s record and both drugs’ information, never the open internet. AI can make mistakes, so always check with your doctor or pharmacist.
References (3)
- Product Information: GEODON(R) oral capsules, ziprasidone oral capsules. Viatris Specialty LLC(per FDA), Morgantown, WV, 2025. DailyMed
- US Food and Drug Administration (FDA): Drug Safety Communications: FDA urges caution about withholding opioid addiction medications from patients taking benzodiazepines or CNS depressants: careful medication management can reduce risks. US Food and Drug Administration (FDA). Silver Spring, MD. 2017.
- Product Information: BRIXADI(TM) subcutaneous extended-release injection, buprenorphine subcutaneous extended-release injection. Braeburn Inc (per FDA), Plymouth Meeting, PA, 2023. DailyMed
Other Serious Interactions of Ziprasidone and Buprenorphine
Also serious with Buprenorphine
- DronedaroneContraindicated
- FluconazoleContraindicated
- IsocarboxazidContraindicated
- KetoconazoleContraindicated
Also serious with Ziprasidone
These Medications Also Interact With Supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
With Buprenorphine
- GrapefruitMajor
- St. John's WortMajor
- Activated CharcoalMajor
- KavaMajor
- WineMajor
- 1,4-butanediolMajor
- BeerMajor
- Gamma-hydroxybutyrate (GHB)Major
- + 210 more
With Ziprasidone
- GrapefruitMajor
- St. John's WortMajor
- Activated CharcoalMajor
- American HelleboreMajor
- ArsenicMajor
- CesiumMajor
- EphedraMajor
- Indian SnakerootMajor
- + 184 more
Check everything you take with our drug–supplement interaction checker.
Still Have Questions About This Combination?
Every question gets a real answer from a licensed pharmacist — free, as soon as they can.
About This Library
Built in-house, documented one interaction at a time. Our interaction database is not a complete list of every known interaction: a combination that isn't listed here hasn't been documented by us yet, which never means it's safe. Checking everything you take at once? Ask your pharmacist to review your full medication list. How we build and review it →
What Each Rating Means
Severity Levels
- Contraindicated These should generally not be used together. This interaction.
- Major Potentially serious — often needs a change or close monitoring.
- Moderate Can be significant — usually manageable with monitoring.
- Minor Usually limited clinical impact.
Evidence Grades
- EstablishedWell documented — supported by controlled studies or strong clinical data.
- ProbableGood supporting evidence, though not definitively proven. This interaction.
- SuspectedSome evidence suggests this interaction, but it is not well established.
- PossibleLimited or conflicting evidence; the interaction may occur.
- TheoreticalExpected from how the drugs work, or from studies of similar drugs; this exact pair has little direct study.
How Soon It Shows
- RapidEffects can appear quickly, often within about 24 hours of combining the drugs.
- DelayedEffects tend to build up gradually over days to weeks.
- UnspecifiedThe timing of this interaction is not well characterized. This interaction.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.